Smart Money · Holder IQ
57.3 / 100
Below median holder quality (percentile 46.4 this quarter). Tracked high-scoring holders are adding shares.
CTOR
Citius Oncology, Inc.NASDAQ
$0.52-5.87%
Close Nov 12, 2026
Reading stored signals…
Healthcare • Drug Manufacturers - Specialty & Generic
Factor tilt: Micro-Cap Blend
People-network credibilityUncalibrated
No reporting owner has a RED or GREEN connection distinguishable from zero in this publication.
Show all 11 reporting owners
- Jaime BartushakChief Financial Officer — as filedRED 0 · GREEN 0 · Net 0
- Myron CzuczmanChief Medical Officer — as filedRED 0 · GREEN 0 · Net 0
- Suren G. DutiaDirector — as filedRED 0.000002 · GREEN 0 · Net -0.000002
- Myron Z. HolubiakSecretary · Director — as filedRED 0.000001 · GREEN 0 · Net -0.000001
- Eugene Myron HolukaDirector — as filedRED 0.000001 · GREEN 0 · Net -0.000001
- Joel David MayersohnDirector — as filedRED 0 · GREEN 0 · Net 0
- Leonard L. MazurChief Executive Officer · Director — as filedRED 0.000001 · GREEN 0 · Net -0.000001
- Dennis M. McGrathDirector — as filedRED 0.000002 · GREEN 0 · Net -0.000002
- Jonathan PeriDirector — as filed
- Robert Joseph SmithDirector — as filedRED 0 · GREEN 0 · Net 0
- Carol WebbDirector — as filedRED 0.000001 · GREEN 0 · Net -0.000001
How this is measured
A connection is distinguishable from zero here only when its RED or GREEN published interval has a lower bound above zero. A person with an admitted finding is always listed first, even with a zero score. Connections are then ordered by the larger of RED and GREEN. A zero tied with other owners is not given a percentile.
RED measures graph connections to people with admitted adjudications; GREEN measures connections to repeat value creators and stewards of qualifying compounders and long-term shareholder-return leaders. Net is GREEN minus RED on a −1 to 1 scale, not a probability or expected return. Connections alone do not establish conduct. These measures are separate from insider trading performance and Company Quality Grade.
The publication is uncalibrated. Its intervals are published bands, not a claim of calibrated confidence or a tested forecast.
Admitted findings are published guilty pleas, convictions and litigated SEC judgments or orders. Settlements and open cases are not findings. A positive net does not erase an admitted finding. Absence of a finding is not a clearance or a complete regulatory-history search.
Reporting owners who filed from after Oct 9, 2025 through Oct 9, 2026: a 12-month window ending at the publication date. This can include former officers and directors; it is not a verified roster of today's employees.
Link an account to see your stake, watchlist and past holdings. use the cited filings to check the reported role and evidence alongside your investment thesis. A connection alone does not tell you to increase or reduce a holding.
Medians across all 10 scored reporting owners at this company as of Oct 9, 2026: RED 0.000001, GREEN 0, net -0.000001. Highest RED: 0.000002; highest GREEN: 0.
- Issuer CIK
- 0001851484
- Publication as of
- Oct 9, 2026; known by Oct 9, 2026
- Retrieved
- Nov 13, 2026; a new publication can take up to six hours to appear here
- RED source refresh state
- fresh within 8d
- Method
- epg.signed_credibility.raw-uncalibrated.v1
- Population identity
- sha256:733e7e30f755f296f1d478ccb2c8674cb0adf04ebbe89319e08bc8255dddb9c5
- Graph identity
- c6521b138848011b775d9a6dfb7ac59989b2082fdc729ef4f41456a4e2037f60
- Source
- SEC Forms 3, 4 and 5 for roles; the Midas Edge API's active immutable people-network publication for credibility and admitted findings. GREEN seed evidence can include vendor price histories. No portfolio or account data is sent to this product.
Jaime Bartushak · SEC CIK 0001725077
Read the Form 4 filed Dec 22, 2025Published intervals: RED 0 to 0.02; GREEN 0 to 0.02; net -0.04 to 0.04.
Score identity: 0f3accaa1310a0a0eaae2e22bd8d005ddac80338dd818f795bfd1295d1c86bdd
Calibration versions: RED affine-identity-unfitted.v1; GREEN affine-identity-unfitted.v1
Myron Czuczman · SEC CIK 0001817716
Read the Form 4 filed Dec 22, 2025Published intervals: RED 0 to 0.02; GREEN 0 to 0.02; net -0.04 to 0.04.
Score identity: d9ae45320f5b1476a6000c9c90a4fe34826e0240de92a9c903d319d6ba2bddc4
Calibration versions: RED affine-identity-unfitted.v1; GREEN affine-identity-unfitted.v1
Suren G. Dutia · SEC CIK 0001514063
Read the Form 4 filed Dec 22, 2025Published intervals: RED 0 to 0.020002; GREEN 0 to 0.02; net -0.040002 to 0.039998.
Score identity: 27125b7c0c7d7eba4cbf40a183aee918790e6e5f14b7fbdbe534f22382e20cf2
Calibration versions: RED affine-identity-unfitted.v1; GREEN affine-identity-unfitted.v1
Myron Z. Holubiak · SEC CIK 0001199080
Read the Form 4 filed Dec 22, 2025Published intervals: RED 0 to 0.020001; GREEN 0 to 0.02; net -0.040001 to 0.039999.
Score identity: 70fc187e49ac477db34d49de05d75cdf578e92c1a2a595cf172cdb03ea3a9100
Calibration versions: RED affine-identity-unfitted.v1; GREEN affine-identity-unfitted.v1
Eugene Myron Holuka · SEC CIK 0001678292
Read the Form 4 filed Dec 22, 2025Published intervals: RED 0 to 0.020001; GREEN 0 to 0.02; net -0.040001 to 0.039999.
Score identity: a974065f24b8402c3123675ab0de7aed9465ffcb99df5d53084e08bc6a8ec401
Calibration versions: RED affine-identity-unfitted.v1; GREEN affine-identity-unfitted.v1
Joel David Mayersohn · SEC CIK 0001588395
Read the Form 4 filed Dec 22, 2025Published intervals: RED 0 to 0.02; GREEN 0 to 0.02; net -0.04 to 0.04.
Score identity: 180ba46d0bd05f98b34cae9589a511396ed1008d7bd1a87d63b938b10261e768
Calibration versions: RED affine-identity-unfitted.v1; GREEN affine-identity-unfitted.v1
Leonard L. Mazur · SEC CIK 0001463414
Read the Form 4 filed Dec 22, 2025Published intervals: RED 0 to 0.020001; GREEN 0 to 0.02; net -0.040001 to 0.039999.
Score identity: 8d5c27d76e7992031ef77782067059a781951a4d4c66a5e1c94af7e022d29507
Calibration versions: RED affine-identity-unfitted.v1; GREEN affine-identity-unfitted.v1
Dennis M. McGrath · SEC CIK 0001269340
Read the Form 4 filed Dec 22, 2025Published intervals: RED 0 to 0.020002; GREEN 0 to 0.02; net -0.040002 to 0.039998.
Score identity: 515de3ac36af9aa8192ed8d20903d9afe6b696a05b0f1a76210841102554c8e7
Calibration versions: RED affine-identity-unfitted.v1; GREEN affine-identity-unfitted.v1
Jonathan Peri · SEC CIK 0002149660
Read the Form 3 filed Aug 14, 2026Score identity: 5f3a2891cada664761326fcab41bba83a44578fa3c8c2229c9c1884acf9a4f32
Robert Joseph Smith · SEC CIK 0002008764
Read the Form 4 filed Dec 22, 2025Published intervals: RED 0 to 0.02; GREEN 0 to 0.02; net -0.04 to 0.04.
Score identity: 3fed0d0dcdb9a4de510c42400e04c413aed524562d2a40a52666938251dd2ddb
Calibration versions: RED affine-identity-unfitted.v1; GREEN affine-identity-unfitted.v1
Carol Webb · SEC CIK 0001671111
Read the Form 4 filed Dec 22, 2025Published intervals: RED 0 to 0.020001; GREEN 0 to 0.02; net -0.040001 to 0.039999.
Score identity: a741e5d0a02dbc1837e6d2839936dfe83b031dfcab412702bf6b0962020595fa
Calibration versions: RED affine-identity-unfitted.v1; GREEN affine-identity-unfitted.v1
- Market cap
- $56.35M
- 1 month
- -33.3%
- 3 months
- -42.6%
- 1 year
- -61.9%
- 52-week range
- $0.49$1.64
More market facts
- Dividend
- No dividends on record
- Short interest
- 0.7% of float201.9K shares · settled Oct 30, 2026 · -11.2% since Oct 15, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $7.11M
- Net income
- -$46.06M
- Free cash flow
- -$19.71M
- Book value
- $40.38M
- Total debt
- $10.21M
- P/E
- —
- Price / sales
- 7.9×
- Price / book
- 1.4×
- FCF yield
- -35.0%
- Net margin
- -648.3%
Trailing twelve-month statements · as of Nov 12, 2026
End-of-day close from stored market data, not a live quote.
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
- Website
- citiusonc.com
- Headquarters
- Cranford, NJ, United States
- Listed
- Dec 8, 2022
- Fiscal year ends
- September
Company profile stored Nov 2, 2026.
Quarterly results
The last 8 fiscal quarters from the latest stored normalized financial statements. These may include restatements. Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Jun 30, 2026 | $1.5M | — | -48.1% | -$8.7M | -$8.9M |
| Mar 2026filed May 15, 2026 | $1.7M | — | 80.3% | -$28.6M | -$26.6M |
| Dec 2025filed Dec 31, 2025 | $3.9M | — | 80.0% | -$5.3M | -$5.5M |
| Sep 2025filed Sep 30, 2025 | — | — | — | -$4.7M | -$5.0M |
| Jun 2025filed Jun 30, 2025 | — | — | — | -$4.9M | -$5.4M |
| Mar 2025filed Mar 31, 2025 | — | — | — | -$7.5M | -$7.7M |
| Dec 2024filed Dec 31, 2024 | — | — | — | -$6.4M | -$6.7M |
| Sep 2024filed Sep 30, 2024 | — | — | — | -$6.7M | -$6.8M |
Balance sheet · cash, debt and near-term obligations
What resources sit beside the obligations? These are balances at each fiscal quarter end, not cash earned during the quarter. Amounts are in USD, the reporting currency.
As of
- Reported cash
- $16.6M
- Reported total debt
- $10.2M
- Current assets
- $42.7M
- Current liabilities
- $58.8M
Vendor filing date:
As of
- Reported cash
- $2.6M
- Reported total debt
- $3.8M
- Current assets
- $29.4M
- Current liabilities
- $58.8M
Vendor filing date:
As of
- Reported cash
- $7.3M
- Reported total debt
- $3.8M
- Current assets
- $37.1M
- Current liabilities
- $44.7M
Vendor filing date:
As of
- Reported cash
- $3.9M
- Reported total debt
- $3.8M
- Current assets
- $27.5M
- Current liabilities
- $49.5M
Vendor filing date:
Link an account to see your stake, watchlist and past holdings. Compare cash and debt across dates when reviewing its reliance on financing. Current assets can include receivables and inventory; current liabilities include bills as well as borrowings. They are not all spendable cash or all debt. These figures alone do not establish the ability to repay.
Source: the latest stored normalized balance sheets, matched to the same security and fiscal end as these income periods. They may include restatements and are not an originally-filed or knowledge-time history. No net debt, coverage ratio or replacement balance is calculated. Read the SEC guide to financial statements for the distinction between balances and cash flows.
Fiscal years · last 5
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2025filed Sep 30, 2025 | — | — | — | -$23.5M | -$24.8M |
| Sep 2024filed Sep 30, 2024 | — | — | — | -$20.6M | -$21.1M |
| Sep 2023filed Sep 30, 2023 | — | — | — | -$12.1M | -$12.7M |
| Sep 2022filed Sep 30, 2022 | — | — | — | -$9.7M | -$10.9M |
| Sep 2021filed Dec 31, 2021 | — | — | — | — | -$10.1K |
Annual cash generation
Does profit turn into cash? Compare CTOR’s accounting profit with operating cash flow and capital spending. Amounts are in USD.
Fiscal year ending
- Net income
- -$24.8M
- Operating cash flow
- -$5.5M
- Capital spending
- $4.0
- Free cash flow
- -$5.5M
Fiscal year ending
- Net income
- -$21.1M
- Operating cash flow
- $126.4K
- Capital spending
- $4.0
- Free cash flow
- $126.3K
Fiscal year ending
- Net income
- -$12.7M
- Operating cash flow
- -$601.3K
- Capital spending
- $4.0
Earlier cash-flow years
Fiscal year ending
- Net income
- -$10.9M
- Operating cash flow
- -$48.0K
- Capital spending
- $0.0
Link an account to see your stake, watchlist and past holdings. Compare cash generation and investment needs with your thesis. Working capital and non-cash charges can separate profit from cash. Capital spending can reduce free cash flow while earnings rise. For a long or short position, that gap alone does not predict a price move.
Cash-flow source and meaning
Source: Annual financial statements, latest stored vendor-normalized figures. These may include restatements and may differ from the filer’s own XBRL. A filing date is not the knowledge date of this version of the values.
Free cash flow is the vendor’s reported figure, shown only when it agrees with operating cash flow less capital spending recorded as a positive outflow. It is not cash guaranteed for dividends or buybacks, and it does not subtract every financing obligation. Missing or sign-incompatible inputs are not filled in. An unlabelled currency is used only for a confirmed domestic USD filer. These are annual statements, not forecasts or an originally-filed history.
Cash allocation: dividends, shares and debt
Where did CTOR’s financing cash go? Compare cash paid as dividends with net share and debt transactions across fiscal years. Amounts are in USD, the reporting currency. These are company-wide totals, not per-share payouts.
Fiscal year ended
Vendor filing date:
- Net borrowing / repayment
- $0.0
- Total financing cash flow
- $15.2M
Fiscal year ended
Vendor filing date:
- Net borrowing / repayment
- $3.8M
- Total financing cash flow
- $4.9M
Fiscal year ended
Vendor filing date:
- Net borrowing / repayment
- $0.0
- Total financing cash flow
- $1.7M
Fiscal year ended
Vendor filing date:
- Total financing cash flow
- $67.7M
Link an account to see your stake, watchlist and past holdings. Compare these uses of cash with operating cash generation and the debt on the balance sheet. A negative net share movement means purchases exceeded issuance; it does not give gross buybacks. A dividend or share purchase can be financed with borrowing, and none of these flows guarantees a future payment or price return.
Allocation source and sign conventions
Source: Annual cash-flow statements, latest stored vendor-normalized values for the same security and fiscal year. These can include restatements; a filing date is not the knowledge date of this version.
Dividends are positive cash paid out. For net share transactions, net borrowing and total financing, positive means cash in and negative means cash out. Net share transactions combine issuance and purchases; they are not gross repurchases, a change in shares outstanding, or stock compensation. Total financing includes other flows and is not the sum of just these three lines. Zero means a reported zero. No FX conversion, shareholder-return total or forecast is inferred.
Short-interest history
Reported short positions, stored float percentages and adjusted prices over the same period.
Shares short
Share of float
Adjusted close · USD
Settlement records · 54 observations
Settlement Oct 30, 2026
201,913 shares short
-25,542 shares (-11.2%) vs Oct 15, 2026
0.7% of the stored float. Published Nov 10, 2026.
Settlement Oct 15, 2026
227,455 shares short
-62,262 shares (-21.5%) vs Sep 30, 2026
0.7% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
289,717 shares short
-219,826 shares (-43.1%) vs Sep 15, 2026
0.9% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
509,543 shares short
+40,578 shares (+8.7%) vs Aug 31, 2026
2.9% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
468,965 shares short
+16,552 shares (+3.7%) vs Aug 14, 2026
Published Sep 10, 2026.
Settlement Aug 14, 2026
452,413 shares short
+53,001 shares (+13.3%) vs Jul 31, 2026
Published Aug 25, 2026.
Settlement Jul 31, 2026
399,412 shares short
+34,262 shares (+9.4%) vs Jul 15, 2026
Published Aug 11, 2026.
Settlement Jul 15, 2026
365,150 shares short
-88,203 shares (-19.5%) vs Jun 30, 2026
Published Jul 24, 2026.
Settlement Jun 30, 2026
453,353 shares short
-44,003 shares (-8.8%) vs Jun 15, 2026
Published Jul 10, 2026.
Settlement Jun 15, 2026
497,356 shares short
-134,377 shares (-21.3%) vs May 29, 2026
Published Jun 25, 2026.
Settlement May 29, 2026
631,733 shares short
+147,471 shares (+30.5%) vs May 15, 2026
Published Jun 9, 2026.
Settlement May 15, 2026
484,262 shares short
-170,804 shares (-26.1%) vs Apr 30, 2026
Published May 27, 2026.
Settlement Apr 30, 2026
655,066 shares short
-279,802 shares (-29.9%) vs Apr 15, 2026
Published May 11, 2026.
Settlement Apr 15, 2026
934,868 shares short
-121,346 shares (-11.5%) vs Mar 31, 2026
Published Apr 24, 2026.
Settlement Mar 31, 2026
1,056,214 shares short
+14,296 shares (+1.4%) vs Mar 13, 2026
Published Apr 10, 2026.
Settlement Mar 13, 2026
1,041,918 shares short
+56,758 shares (+5.8%) vs Feb 27, 2026
Published Mar 24, 2026.
Settlement Feb 27, 2026
985,160 shares short
+71,608 shares (+7.8%) vs Feb 13, 2026
Published Mar 10, 2026.
Settlement Feb 13, 2026
913,552 shares short
-299,590 shares (-24.7%) vs Jan 30, 2026
Published Feb 25, 2026.
Settlement Jan 30, 2026
1,213,142 shares short
+10,335 shares (+0.9%) vs Jan 15, 2026
Published Feb 10, 2026.
Settlement Jan 15, 2026
1,202,807 shares short
+218,930 shares (+22.3%) vs Dec 31, 2025
Published Jan 27, 2026.
Settlement Dec 31, 2025
983,877 shares short
+333,333 shares (+51.2%) vs Dec 15, 2025
Published Jan 12, 2026.
Settlement Dec 15, 2025
650,544 shares short
+428,845 shares (+193.4%) vs Nov 28, 2025
Published Dec 24, 2025.
Settlement Nov 28, 2025
221,699 shares short
-18,540 shares (-7.7%) vs Nov 14, 2025
Published Dec 9, 2025.
Settlement Nov 14, 2025
240,239 shares short
-11,120 shares (-4.4%) vs Oct 31, 2025
Published Nov 25, 2025.
Settlement Oct 31, 2025
251,359 shares short
+100,457 shares (+66.6%) vs Oct 15, 2025
Published Nov 11, 2025.
Settlement Oct 15, 2025
150,902 shares short
-18,126 shares (-10.7%) vs Sep 30, 2025
Published Oct 24, 2025.
Settlement Sep 30, 2025
169,028 shares short
+33,283 shares (+24.5%) vs Sep 15, 2025
Published Oct 9, 2025.
Settlement Sep 15, 2025
135,745 shares short
-167,615 shares (-55.3%) vs Aug 29, 2025
Published Sep 24, 2025.
Settlement Aug 29, 2025
303,360 shares short
+66,593 shares (+28.1%) vs Aug 15, 2025
Published Sep 10, 2025.
Settlement Aug 15, 2025
236,767 shares short
-62,287 shares (-20.8%) vs Jul 31, 2025
Published Aug 26, 2025.
Settlement Jul 31, 2025
299,054 shares short
+222,517 shares (+290.7%) vs Jul 15, 2025
Published Aug 11, 2025.
Settlement Jul 15, 2025
76,537 shares short
-289,436 shares (-79.1%) vs Jun 30, 2025
Published Jul 24, 2025.
Settlement Jun 30, 2025
365,973 shares short
+252,393 shares (+222.2%) vs Jun 13, 2025
Published Jul 10, 2025.
Settlement Jun 13, 2025
113,580 shares short
+88,080 shares (+345.4%) vs May 30, 2025
Published Jun 25, 2025.
Settlement May 30, 2025
25,500 shares short
-21,600 shares (-45.9%) vs May 15, 2025
Published Jun 10, 2025.
Settlement May 15, 2025
47,100 shares short
-23,901 shares (-33.7%) vs Apr 30, 2025
Published May 27, 2025.
Settlement Apr 30, 2025
71,001 shares short
-134,691 shares (-65.5%) vs Apr 15, 2025
Published May 9, 2025.
Settlement Apr 15, 2025
205,692 shares short
+25,163 shares (+13.9%) vs Mar 31, 2025
Published Apr 25, 2025.
Settlement Mar 31, 2025
180,529 shares short
+152,648 shares (+547.5%) vs Mar 14, 2025
Published Apr 9, 2025.
Settlement Mar 14, 2025
27,881 shares short
-9,857 shares (-26.1%) vs Feb 28, 2025
Published Mar 25, 2025.
Settlement Feb 28, 2025
37,738 shares short
+5,150 shares (+15.8%) vs Feb 14, 2025
Published Mar 11, 2025.
Settlement Feb 14, 2025
32,588 shares short
-4,540 shares (-12.2%) vs Jan 31, 2025
Published Feb 26, 2025.
Settlement Jan 31, 2025
37,128 shares short
+14,242 shares (+62.2%) vs Jan 15, 2025
Published Feb 11, 2025.
Settlement Jan 15, 2025
22,886 shares short
-61,563 shares (-72.9%) vs Dec 31, 2024
Published Jan 27, 2025.
Settlement Dec 31, 2024
84,449 shares short
+7,117 shares (+9.2%) vs Dec 13, 2024
Published Jan 10, 2025.
Settlement Dec 13, 2024
77,332 shares short
+45,584 shares (+143.6%) vs Nov 29, 2024
Published Dec 24, 2024.
Settlement Nov 29, 2024
31,748 shares short
+1,981 shares (+6.7%) vs Nov 15, 2024
Published Dec 10, 2024.
Settlement Nov 15, 2024
29,767 shares short
-9,650 shares (-24.5%) vs Oct 31, 2024
Published Nov 26, 2024.
Settlement Oct 31, 2024
39,417 shares short
+28,820 shares (+272%) vs Oct 15, 2024
Published Nov 11, 2024.
Settlement Oct 15, 2024
10,597 shares short
-40,942 shares (-79.4%) vs Sep 30, 2024
Published Oct 24, 2024.
Settlement Sep 30, 2024
51,539 shares short
+50,366 shares (+4,293.8%) vs Sep 13, 2024
Published Oct 9, 2024.
Settlement Sep 13, 2024
1,173 shares short
-23,324 shares (-95.2%) vs Aug 30, 2024
Published Sep 24, 2024.
Settlement Aug 30, 2024
24,497 shares short
-18,002 shares (-42.4%) vs Aug 15, 2024
Published Sep 11, 2024.
Settlement Aug 15, 2024
42,499 shares short
Published Aug 26, 2024.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records. Adjusted prices exclude a reused ticker’s earlier issuer. FINRA data and reporting dates · How to read short interest
Portfolio context
Link an account to see your stake, watchlist and past holdings.
We’ll show you if CTOR is in your portfolio and how much it contributes.
Sign inMarket context
Smart money context
Holder IQ: MEDIUM
2 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Red flags
Red flags: 21
Largest 13-F holders · Q2 2026
19 filers reported a long position in CTOR for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
99.5%
of the 14.1M shares 13-F filers reported
Moves vs Q1 2026
2 added2 trimmed
1 new · 5 unchanged
Net shares held
-1.4%
across the 9 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | Armistice Capital, LLC | $5.7M · 8.7M shares | 8.7M | -5.3% |
| 2 | Bank of America Corp | $2.5M · 3.8M shares | 3.8M | Unchanged |
| 3 | Vanguard Capital Management LLC | $355.1K · 546.3K shares | 546.3K | +2.2% |
| 4 | UBS Group AG | $217.5K · 334.6K shares | 334.6K | +808.3% |
| 5 | Geode Capital Management, LLC | $159.5K · 245.4K shares | 245.4K | -7.3% |
| 6 | Vanguard Fiduciary Trust Co | $79.2K · 121.9K shares | 121.9K | Unchanged |
| 7 | IFP Advisors, Inc | $69.8K · 107.4K shares | 107.4K | Unchanged |
| 8 | Citadel Advisors LLC | $58.9K · 90.6K shares | 90.6K | New |
| 9 | Northern Trust Corp | $29.7K · 45.7K shares | 45.7K | Unchanged |
| 10 | State Street Corp | $27.9K · 42.9K shares | 42.9K | Unchanged |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of CTOR file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Aug 14, 2026 | Armistice Capital, LLC13G · passive · amended | 9.99% |
| Jun 4, 2026 | Citius Pharmaceuticals Inc13D · activist · amended | 71% |
Moves the factor model did not explain
How much of CTOR’s move accompanied the market and its measured style leanings, and how much was left? The residual is unexplained by this fitted model. It does not establish a cause, skill or future alpha.
Return split unavailable. A complete, reconciled model for every market session in this window is unavailable. Missing dates are not filled.
Link an account with dated transactions to see what share of your own holding’s move since its purchase-date close was unexplained, with long and short positions distinguished. Your private holdings never enter this public chart.
Dated model observations (20)
Daily percentage returns, not window contributions. Source: the same dated warehouse rows and model v1.2.0; observed 2026-11-13T16:02:49.816Z. Absent sessions are never interpolated; missing or failed inputs stay unavailable.
| Date | Stock | Market | Styles | Residual |
|---|---|---|---|---|
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable |
How this split is calculated
Each day uses that day’s fitted market intercept and style exposures multiplied by that day’s published factor returns. Their sum plus the independently stored residual must reconcile to the stock return. Window effects are weighted by stock wealth at each day’s start and added; the stock return compounds. Every expected US market session must be present and pass source, identity, model and numerical checks. This retrospective fit is an explanation of measured returns, not evidence of causation or an investable forecast. The window ends at the latest published model session, which can lag the market; today’s unfinished session is excluded.
What insiders reported owning
Reading dated filing evidence…
Get the Full Analysis for CTOR
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.